Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1623 1656 1673 1693 3762
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17584129 | METHODS AND THERAPIES FOR TREATING ATHEROSCLEROSIS AND/OR HYPERLIPIDEMIA USING OLIGOSACCHARIDES | Non-Final OA | The Regents of the University of California |
| 18449862 | PROCESS FOR THE DE-TRITYLATION OF OLIGONUCLEOTIDES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18017297 | METHOD FOR MODULATING THE BLADDER MICROBIOME TO IMPROVE BLADDER HEALTH | Final Rejection | Kimberly-Clark Worldwide, Inc. |
| 18405347 | RESTORING PHYSIOLOGY WITH SMALL MOLECULE MIMICS OF MISSING PROTEINS | Non-Final OA | The Board of Trustees Of The University Of Illinois |
| 17904211 | LONG CHAIN CARBON AND CYCLIC AMINO ACIDS SUBSTRATES FOR GENETIC CODE REPROGRAMMING | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18261012 | SYNBIOTIC TREATMENT REGIMENS | Non-Final OA | PROLACTA BIOSCIENCE, INC. |
| 18361713 | COMPOSITIONS AND METHODS FOR MAKING AND USING DOUBLE NETWORK HYDROGELS | Non-Final OA | The Regents of the University of Colorado, a Body Corporate |
| 17674177 | POLYNUCLEOTIDE CAPTURE MATERIALS, AND SYSTEMS USING SAME | Non-Final OA | HANDYLAB, INC. |
| 18883520 | TARGETED COMPOSITIONS | Non-Final OA | ARBUTUS BIOPHARMA CORPORATION |
| 18479576 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | Non-Final OA | Gilead Sciences, Inc. |
| 18284175 | PHARMACEUTICAL COMPOSITION CONTAINING AUCUBIN FOR PREVENTING OR TREATING MACULAR DEGENERATION | Non-Final OA | INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY |
| 18425427 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | Non-Final OA | LUNELLA BIOTECH, INC. |
| 17997787 | METHOD FOR IDENTIFYING RNA BINDING PROTEIN BINDING SITES ON RNA | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18533937 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | Non-Final OA | Glycosynnovations PTY LTD |
| 18556642 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | Non-Final OA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT |
| 18287530 | NUTRITIONAL SUPPLEMENT AND USES | Non-Final OA | Citrox Biosciences Limited |
| 17915943 | PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-CYCLODEXTRIN POLYMER AND USES THEREOF | Non-Final OA | RENATUS INC. |
| 18554006 | TREATMENT OF VIRUS INFECTIONS | Non-Final OA | TX MEDIC AB |
| 18283757 | A VAGINAL CONTRACEPTIVE COMPOSITION FOR REINFORCEMENT OF THE CERVICAL MUCUS BARRIER PROPERTIES | Non-Final OA | CIRQLE BIOMEDICAL CONTRACEPTION APS |
| 18276114 | PHARMACEUTICAL COMPOSITION FOR PREVENTING CYTOKINE STORM | Non-Final OA | KINKI UNIVERSITY |
| 18277982 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE 19, CONTAINING CARBOCYCLIC NUCLEOSIDE DERIVATIVE | Non-Final OA | FUTURE MEDICINE CO., LTD. |
| 18222397 | PORTABLE DEVICE FOR ISOLATING NUCLEIC ACID FROM BLOOD | Final Rejection | KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL |
| 18343296 | METHOD FOR ISOLATING RNA WITH HIGH YIELD | Non-Final OA | QIAGEN GmbH |
| 18201714 | PREBIOTIC FORMULA, DIETARY FIBER, FOOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Final Rejection | BIOCEUTICAL ATTAINMENTS COMPANY LIMITED |
| 17999400 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | Non-Final OA | SERVIER PHARMACEUTICALS LLC |
| 18188101 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS | Non-Final OA | ADJUVANCE TECHNOLOGIES, INC. |
| 16980207 | METHOD OF TREATMENT | Non-Final OA | NUCHIDO LIMITED |
| 17510069 | LOW CONTAMINANT COMPOSITIONS | Final Rejection | ALOPEXX INC. |
| 17598040 | SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM | Final Rejection | Immunophotonics, Inc. |
| 17130195 | USE OF HUMAN MILK OLIGOSACCHARIDES IN CALVES FATTENING | Non-Final OA | OligoScience Biotechnology GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy